Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate.
Polycythemia vera (PV) is a myeloproliferative disease which if untreated leads to thrombohemorrhagic complications and eventually to progressive myelofibrosis of the marrow, anemia, and splenomegaly. Two new drugs are now available, interferon and imatinib mesylate, which may alter the course of this disease. Used as single agents, each produces lasting remissions in about 75% of the cases.
Silver
Richard T
RT
New York Presbyterian-Weill Cornell Medical Center, 1300 York Avenue, Box 581, New York, NY 10021, USA.
D000328:Adult; D000368:Aged; D001549:Benzamides; D001792:Blood Platelets / Q000187:drug effects; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004920:Erythropoiesis / Q000187:drug effects; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007155:Immunologic Factors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007370:Interferon Type I / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018962:Phlebotomy; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011087:Polycythemia Vera / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000502:physiology; D011743:Pyrimidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012074:Remission Induction; D013163:Splenomegaly / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome
D001549:Benzamides; D007155:Immunologic Factors; D007370:Interferon Type I; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011994:Recombinant Proteins; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit